Almirall's third quarter results boosted by aclidinium sales

11 November 2013

Spain's largest drugmaker Almirall (ALM: MC) has released third quarter 2013 financial results reporting net sales of 511.3 million euros ($684.9 million).

This was 3.7% down on last year’s quarter sales of 531.1 million euros, but the company said this reflected the higher quarter results in 2012 which were caused by high sales of chronic obstructive pulmonary disease (COPD) drug Eklira/Bretaris Genuair (aclidinium bromide) after approvals by the US Food and Drug Administration and the European Medicines Agency.

Total revenues were 611.4 million euros, down 13.5% from 706.7 million euros year-on-year. EBIT (earnings before interest and taxes) and net EBITDA decreased to 7.6 million euros, down 92.4%, and 59.3 million, down 60.5%, respectively. The company says it is in line to achieve 2013 full year financial targets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK